Clinical Trials
22 trialsNCT04364178 2026-05-27
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
Phase 1/2 Terminated
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT02875613 2024-08-28
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
University of California, San Diego
Phase 2 Terminated
NCT05305040 2024-05-16
Prevent
AlloVir
Phase 2/3 Terminated
NCT04693637 2024-05-09
Prevent
AlloVir
Phase 2/3 Completed
NCT03682055 2023-08-15
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
Phase 1/2 Terminated
NCT00834093 2023-06-28
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT02496676 2022-03-02
Magnesium Supplementation in People With XMEN Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT02108522 2021-07-20
CHARMS
AlloVir
Phase NA Completed
NCT00267865 2020-06-01
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT02000817 2019-06-24
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
GlaxoSmithKline
Phase 1/2 Completed
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT02763254 2019-03-26
CIVIC
Cell Medica Ltd
Phase 2 Terminated
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT01058239 2018-02-15
Bortezomib Plus Rituximab for EBV+ PTLD
Massachusetts General Hospital
Phase 2 Completed
NCT00575185 2017-03-22
Mono6
University of Minnesota
Phase 1/2 Completed